What is the 13F Pro Quality Score for ENOV?

13F Pro ranks Enovis CORP (ENOV) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ENOV's current score at https://13fpro.ai/research/ENOV (free sign-up required for the full ranking).

Which hedge funds own the most ENOV stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ENOV include BlackRock,, AMERICAN CENTURY COMPANIES, LINDEN ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ENOV as soon as new 13F filings post.

Where does 13F Pro source ENOV data?

All Enovis CORP fundamentals and ownership data come directly from SEC EDGAR. Enovis CORP files with the SEC under CIK 1420800. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ENOV in?

Enovis CORP (ENOV) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ENOV research updated on 13F Pro?

ENOV's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Enovis CORP(ENOV)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1420800 ENOV stock profile & AI dashboard →

13F Pro Quality Score

40.5/100

Rank #1,938 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

71.4/100

Profitability

12.7/100

Balance Sheet

12.8/100

Earnings Quality

30.0/100

Free Cash Flow

40.5/100

Institutional Flow

42.2/100

Revenue Scale

64.7/100

Dilution Risk

47.5/100

ENOV Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Enovis CORP (ENOV), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ENOV at 40.5/100 on a 32-signal composite quality model, placing it at rank #1,938 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (12.7) and balance sheet strength (12.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 47.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Enovis CORP reports quarterly revenue of $589.2M, net income of $-8.8M, free cash flow of $-28.9M. Top institutional holders of ENOV by reported 13-F value include BlackRock,, AMERICAN CENTURY COMPANIES, LINDEN ADVISORS, based on the most recent SEC filings. ENOV trades on the NYSE exchange and files with the SEC under CIK 1420800. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ENOV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Enovis CORP directly from SEC EDGAR. Enovis CORP's 13F Pro composite quality score has ranged between 8 and 63 since 2022, currently 40.5 — a stable long-term trajectory across 51 quarterly and live scoring snapshots.

✦

Fun facts about Enovis CORP

Quirks, history, and lore behind ENOV — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical technology company · mid-cap · listed on the NYSE · focused on musculoskeletal health and orthopedic devices.
2
The Numbers
Annual revenue in the neighborhood of $2 billion, with operations spanning over 20 countries and thousands of employees worldwide.
3
The History
The company traces its roots to Colfax Corporation, which spun off its medical device segment in 2022 to let it stand on its own two (hopefully well-braced) feet.
4
The Secret
Its portfolio spans everything from bracing and joint supports to surgical reconstruction implants — if your bones are having a bad day, this company probably makes something for that.
5
The Lore
It absorbed the well-known DJO Global brand, one of the largest makers of orthopedic braces and rehabilitation products in the world, giving it a massive foothold in non-surgical care.
6
The Giveaway
Its ticker spells out a word meaning innovation, and the company literally put "innovation" in its own name — Eno- as in enabling, -vis as in vision. Braces, implants, and a very on-the-nose rebrand.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$589.2M

Net Income

Q1 2026

$-8.8M

Free Cash Flow

Q1 2026

$-28.9M

D/E Ratio

Q1 2026

0.92

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+6.7% YoY

$2.25BFY 2025

FY20 $1.12BFY21 $1.43BFY24 $2.11BFY25 $2.25B

Net Income

-43.5% YoY

$-1.18BFY 2025

FY20 $42.6MFY21 $71.7MFY24 $-825.5MFY25 $-1.18B

Operating Income

-44.9% YoY

$-1.12BFY 2025

FY20 $-66.2MFY21 $-62.8MFY24 $-775.7MFY25 $-1.12B

EPS (Diluted)

-39.0% YoY

$-20.75FY 2025

FY20 $0.93FY21 $1.40FY24 $-14.93FY25 $-20.75

Total Assets

-18.7% YoY

$3.83BFY 2025

FY20 $7.35BFY21 $8.52BFY24 $4.72BFY25 $3.83B

Total Debt

-1.3% YoY

$1.33BFY 2025

FY20 $2.26BFY21 $2.09BFY24 $1.35BFY25 $1.33B

Op. Cash Flow

+91.4% YoY

$217.3MFY 2025

FY20 $301.9MFY21 $356.1MFY24 $113.5MFY25 $217.3M

Metric	FY 2025	FY 2024	FY 2021	FY 2020	FY 2019	FY 2017
Revenue	$2.25B +6.7%	$2.11B +47.8%	$1.43B +27.3%	$1.12B -66.3%	$3.33B +0.8%	$3.30B
Net Income	$-1.18B -43.5%	$-825.5M -1252.0%	$71.7M +68.1%	$42.6M +108.1%	$-527.6M -449.2%	$151.1M
Operating Income	$-1.12B -44.9%	$-775.7M -1135.2%	$-62.8M +5.1%	$-66.2M -132.5%	$203.6M +50.2%	$135.6M
EPS (Diluted)	$-20.75 -39.0%	$-14.93 -1166.4%	$1.40 +50.5%	$0.93 +123.9%	$-3.89 -418.9%	$1.22
Total Assets	$3.83B -18.7%	$4.72B -44.6%	$8.52B +15.8%	$7.35B -0.5%	$7.39B +10.1%	$6.71B
Total Debt	$1.33B -1.3%	$1.35B -35.6%	$2.09B -7.3%	$2.26B -3.5%	$2.34B +119.3%	$1.07B
Operating Cash Flow	$217.3M +91.4%	$113.5M -68.1%	$356.1M +17.9%	$301.9M +130.6%	$130.9M -40.1%	$218.8M

Get alerted when ENOV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Enovis CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ENOV

BlackRock, Inc.
$226.1M9,936,469 sh
AMERICAN CENTURY COMPANIES INC
$108.5M4,768,921 sh
LINDEN ADVISORS LP
$103.4M106,748,000 sh
Context Capital Management, LLC
$102.6M106,093,000 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$86.6M3,808,629 sh
VANGUARD CAPITAL MANAGEMENT LLC
$58.1M2,552,351 sh
DIMENSIONAL FUND ADVISORS LP
$57.9M2,545,922 sh
Rubric Capital Management LP
$55.8M2,453,265 sh
DAVENPORT & Co LLC
$55.5M2,438,241 sh
STATE STREET CORP
$54.7M2,402,235 sh

Fund	Value	Shares
BlackRock, Inc.	$226.1M	9,936,469
AMERICAN CENTURY COMPANIES INC	$108.5M	4,768,921
LINDEN ADVISORS LP	$103.4M	106,748,000
Context Capital Management, LLC	$102.6M	106,093,000
VANGUARD PORTFOLIO MANAGEMENT LLC	$86.6M	3,808,629
VANGUARD CAPITAL MANAGEMENT LLC	$58.1M	2,552,351
DIMENSIONAL FUND ADVISORS LP	$57.9M	2,545,922
Rubric Capital Management LP	$55.8M	2,453,265
DAVENPORT & Co LLC	$55.5M	2,438,241
STATE STREET CORP	$54.7M	2,402,235

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ENOV on your watchlist

Track score changes the day Enovis CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ENOV a good stock to buy?

13F Pro's AI-powered analysis of Enovis CORP (ENOV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ENOV are available on the ENOV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ENOV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ENOV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Enovis CORP's investment landscape.